调节门静脉压力与血流能否促进活体供肝移植受者术后恢复?系统综述与专家小组建议
该文为遵循PRISMA的系统综述与GRADE专家小组建议,检索Ovid MEDLINE、Embase、Scopus、Google Scholar和Cochrane Central,共识别594篇文献,最终纳入24篇(5项随机对照试验、4项前瞻性研究、15项回顾性系列)。工作组短列了6项可能影响活体供肝移植早期恢复的结局指标:急性肾损伤、小肝综合征、包括脓毒症在内的并发症、ICU和住院时间、门静脉流入调节技术的并发症及总死亡率;工作组注意到门静脉流入调节在该亚组受者中对所有结局指标均有有益影响。专家小组推荐术前和术中移植肝实际重量验证、门静脉压力/血流测定及全面供者评估为强制措施,并推荐药物性门静脉流入调节改善早期肾功能、在选择性小肝移植物患者中减少小肝综合征/早期同种异体移植物功能障碍和脓毒症。
要点
- 推荐术前和术中行移植肝实际重量验证、门静脉压力/血流测定及全面供者评估,以判定可能的小肝综合征/小血流移植物(证据质量:中等|推荐强度:强)。
- 药物性门静脉流入调节有助于改善活体供肝移植受者的早期肾功能(证据质量:高|推荐强度:强)。
- 在选择性小肝移植物患者中,门静脉流入调节有助于减少小肝综合征/早期同种异体移植物功能障碍和脓毒症(证据质量:中等|推荐强度:强)。
- 门静脉流入调节采用脾切除术较脾动脉结扎术并发症发生率更高(证据质量:低|推荐强度:强)。
- 在小肝移植物活体供肝移植受者中,门静脉流入调节可能有助于降低并发症/死亡率(证据质量:低|推荐强度:强)。
适用人群与场景
- 活体供肝移植(LDLT)受者,尤其小肝移植物(SFSG)受者。
诊断标准与关键阈值
- 术前和术中移植肝实际重量验证、门静脉压力/血流测定及全面供者评估,用于判定可能的小肝综合征/小血流移植物(质量证据:中等|推荐强度:强)。
处置流程与药物剂量
- 药物性门静脉流入调节用于改善活体供肝移植受者早期肾功能(质量证据:高|推荐强度:强)。
- 在选择性小肝移植物患者中,门静脉流入调节用于减少小肝综合征/早期同种异体移植物功能障碍和脓毒症(质量证据:中等|推荐强度:强)。
- 门静脉流入调节采用脾切除术较脾动脉结扎术并发症发生率更高(质量证据:低|推荐强度:强)。
- 在小肝移植物活体供肝移植受者中,门静脉流入调节可能有助于降低并发症/死亡率(质量证据:低|推荐强度:强)。
研究设计与关键结果
- 系统综述共识别594篇文献,最终纳入24篇由工作组审查,包括5项随机对照试验、4项前瞻性研究和15项回顾性系列。
- 工作组短列了6项可能影响活体供肝移植早期恢复的结局指标:急性肾损伤、小肝综合征、包括脓毒症在内的并发症、ICU和住院时间、门静脉流入调节技术的并发症及总死亡率。
- 工作组注意到门静脉流入调节在该亚组活体供肝移植受者中对所有结局指标均有有益影响。
- 活体供肝移植受者中小肝移植物患者,调节门静脉压力和血流可促进移植后恢复(质量证据:中等|推荐强度:强)。
证据类型、等级与局限
- 证据类型:遵循PRISMA的系统综述与基于GRADE方法的国际专家小组建议(PROSPERO ID:CRD42021260997)。
- 推荐1:术前和术中移植肝实际重量验证、门静脉压力/血流测定及全面供者评估为强制措施(质量证据:中等|推荐强度:强)。
- 推荐2:药物性门静脉流入调节有助于改善活体供肝移植受者早期肾功能(质量证据:高|推荐强度:强)。
- 推荐3:在选择性小肝移植物患者中,门静脉流入调节有助于减少小肝综合征/早期同种异体移植物功能障碍和脓毒症(质量证据:中等|推荐强度:强)。
- 推荐4:门静脉流入调节采用脾切除术较脾动脉结扎术并发症发生率更高(质量证据:低|推荐强度:强)。
- 推荐5:在小肝移植物活体供肝移植受者中,门静脉流入调节可能有助于降低并发症/死亡率(质量证据:低|推荐强度:强)。
- 推荐6:在小肝移植物活体供肝移植受者中,调节门静脉压力和血流可促进移植后恢复(质量证据:中等|推荐强度:强)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对活体供肝移植受者,术前和术中应行移植肝实际重量验证、门静脉压力/血流测定及全面供者评估,以识别可能的小肝综合征/小血流移植物(国际专家小组推荐,质量证据中等|推荐强度强)。
- 对活体供肝移植受者,药物性门静脉流入调节有助于改善早期肾功能(国际专家小组推荐,质量证据高|推荐强度强)。
- 对选择性小肝移植物患者,门静脉流入调节有助于减少小肝综合征/早期同种异体移植物功能障碍和脓毒症(国际专家小组推荐,质量证据中等|推荐强度强)。
- 门静脉流入调节采用脾切除术较脾动脉结扎术并发症发生率更高(国际专家小组推荐,质量证据低|推荐强度强)。
- 对小肝移植物活体供肝移植受者,门静脉流入调节可能有助于降低并发症/死亡率(国际专家小组推荐,质量证据低|推荐强度强)。
- 对小肝移植物活体供肝移植受者,调节门静脉压力和血流可促进移植后恢复(国际专家小组推荐,质量证据中等|推荐强度强)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Portal inflow modulation (PIM) aimed at reducing portal hyperperfusion is commonly used in living donor liver transplantation (LDLT) to reduce the risk of small-for-size syndrome (SFSS). Many different techniques, both pharmacological and surgical have been used for this purpose. There is, however, little consensus on the best method of PIM, its exact role in preventing SFSS and on early post-LDLT recovery.
OBJECTIVES: To identify whether modifications of portal pressures and flows enhance recovery after LDLT and to provide international expert panel recommendations.
DATA SOURCES: Ovid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.
METHODS: Systematic review following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel.
PROSPERO ID: CRD42021260997.
RESULTS: Five hundred and ninety four articles were identified through databases' search. Of the 24 included for a final review by the working group (WG), there were five randomized control trials, four prospective studies and 15 retrospective series. Six outcome measures which were likely to influence early recovery after LDLT, especially in small-for-size grafts (SFSG) were shortlisted. These included acute kidney injury, SFSS, morbidity including sepsis, length of ICU and hospital stay, morbidity of the PIM technique and overall mortality. The WG noted that PIM in this subset of LDLT recipients had a beneficial effect on all the outcomes measures.
CONCLUSIONS: Considering all decision domains, the panel recommends pre- and intraoperative actual graft weight validation, portal pressure/flow measurements, and a comprehensive donor evaluation for the determination of potentially small-for-size/ small-for-flow grafts as mandatory. (Quality of Evidence: Moderate | Grade of Recommendation: Strong) Pharmacological PIM helps improve early renal function in LDLT recipients. (Quality of Evidence: High | Grade of Recommendation: Strong) In selected patients with SFSG, PIM helps reduce SFSS/EAD and sepsis. (Quality of Evidence: Moderate | Grade of Recommendation: Strong) PIM in the form of splenectomy has increased morbidity compared to splenic artery ligation (SAL). (Quality of Evidence: Low | Grade of Recommendation: Strong) In LDLT recipients with SFSG, PIM may help reduce morbidity/mortality. (Quality of Evidence: Low | Grade of Recommendation: Strong) In LDLT recipients with SFSG, modification of portal pressures and flows enhances recovery after LDLT. (Quality of Evidence: Moderate | Grade of Recommendation: Strong).
参考来源
- Rammohan A, Rela M, Kim DS, et al. Does modification of portal pressure and flow enhance recovery of the recipient after living donor liver transplantation? A systematic review of literature and expert panel recommendations. Clin Transplant. 2022. PMID: 35344628. doi:10.1111/ctr.14657
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。